Immutep Ltd
Research Immutep Ltd (IMMP) on Bullrun: market cap USD 528.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMMP
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 528.38M
- Financial periodFY2026
- RevenueAUD 14.56M
- Net income-AUD 79.30M
- Free cash flow-AUD 55.56M
- Gross margin-494.7%
Valuation Snapshot
latest market cap is USD 528.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 14.56M | -AUD 79.30M | -AUD 55.56M | -494.7% | -0.54 | AUD 63.67M | AUD 1.05M | AUD 61.53M |
| FY2025 | n/a | -AUD 61.43M | n/a | n/a | -0.42 | AUD 67.41M | AUD 1.21M | AUD 98.90M |
| FY2024 | AUD 0 | -AUD 42.72M | -AUD 35.75M | n/a | -0.36 | AUD 161.79M | AUD 1.59M | AUD 189.52M |
| FY2023 | AUD 0 | -AUD 39.90M | -AUD 35.44M | n/a | -0.45 | AUD 123.42M | AUD 1.23M | AUD 136.47M |
| FY2022 | AUD 170.37K | -AUD 32.21M | -AUD 30.25M | -15630.8% | -0.38 | AUD 80.00M | AUD 1.73M | AUD 94.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 528.38M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 416.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 315.86M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 287.96M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 157.71M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 287.19M | n/a | n/a | n/a |
About Immutep Ltd
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immutep Ltd's market cap?
Immutep Ltd's market capitalization is USD 528.38M.
What does Immutep Ltd do?
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.